Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DPV 001

Next Previous
Drug Profile

DPV 001

Alternative Names: Autologous DRibble vaccine; Autophagosome cancer vaccine - UbiVac; Cancer vaccine DRibble; DPV-001; DRibble Vaccine

Latest Information Update: 02 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator UbiVac
  • Developer Bristol-Myers Squibb; CanWell Pharma; National Cancer Institute (USA); Providence Health & Services; UbiVac
  • Class Antineoplastics; Cancer vaccines; Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Prostate cancer

Highest Development Phases

  • Phase II Non-small cell lung cancer; Solid tumours
  • Preclinical Gastric cancer; Oesophageal cancer
  • Suspended Triple negative breast cancer
  • No development reported Bladder cancer; Head and neck cancer; Pancreatic cancer; Prostate cancer

Most Recent Events

  • 02 Sep 2026 Phase-II clinical trials in Solid tumours in USA (unspecified route) prior to September 2026 (CanWell Pharma pipeline, September 2026)
  • 22 Apr 2026 Pharmacodynamics data from phase I trial in Head and neck cancer presented at the 117th Annual Meeting of the American Association for Cancer Research (AACR-2026)
  • 28 Jul 2025 No recent reports of development identified for phase-I development in Head-and-neck-cancer(Combination therapy, Metastatic disease, Recurrent, Second-line therapy or greater) in USA (Parenteral)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top